From The Hindu
Center-Left Owned by Kasturi & Sons Ltd.Alembic Pharma Q2 net surges 81% to ₹335 crore
What's behind this
Aurobindo Pharma reported a 32.5% rise in Q2 net profit to ₹1,124 crore, attributing the gain to higher revenue. The company said the strong performance reflected robust business fundamentals, sustained execution and the resilience of its diversified product portfolio.
AI-generated overview from 2 outlets. It summarises their reporting and adds no reporting of its own.
What each side is saying
One outlet's own words from each side of the spectrum. Quoted, not summarised.
-
left · 1 outlet
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
RSS excerpt
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
